EfficacyHigh
Studies12
Participants450
StatusAvailable
Sermorelin
Sermorelin acetate (GHRH 1-29)
Sermorelin is a synthetic 29-amino acid peptide that mimics the biologically active portion of growth hormone releasing hormone (GHRH). Originally FDA-approved in 1997 as Geref® for treating children with growth hormone deficiency, it stimulates the pituitary gland to produce natural growth hormone in physiological pulsatile patterns. Unlike direct growth hormone injections, sermorelin works with the body's feedback mechanisms to prevent overdose and maintain natural GH rhythms.
Clinical Safety Profile
Reported Side Effects
Injection site reactions (pain, redness, swelling)
Mild headache and dizziness
Flushing of face and skin
Transient nausea
Hyperactivity or restlessness
Allergic reactions (rare)
Pain at injection site
Fatigue during initial treatment
Side Effect Management (Clinical Trial Data)
Injection site reactions
Common
18%
Facial flushing
Infrequent
10%
Headache
Infrequent
7%
Nausea
Infrequent
4%
Fatigue
Infrequent
6%
Dizziness
Infrequent
5%
Side Effect Management Strategies
Nausea: Take with food, smaller meals, ginger supplements
Vomiting: Slower dose escalation, anti-emetics if severe
Diarrhea: Adequate hydration, probiotics, bland diet
Constipation: Increase fiber intake, adequate fluids, light exercise
Clinical Safety Metrics
Variable
Overall Safety Rating
Variable
Discontinuation Rate
Research
Approved Status
CONTRAINDICATIONS
• Known allergy to sermorelin or components
• Active malignancy or cancer history
• Severe kidney or liver disease
• Pregnancy and breastfeeding
Medical Disclaimer
Clinical data presented is from peer-reviewed studies. Individual results may vary. Consult healthcare professionals before starting treatment. This information is for educational purposes only.